abiraterone acetate / Generic mfg. - LARVOL DELTA

Long-term overall survival with abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial for de novo metastatic castration-sensitive prostate cancer (mCSPC) (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone sensitive prostate cancer (mHSPC): updated overall survival (OS) from CAPItello-281 (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • PTEN

Eugonadal Progression-Free Survival Following Intensification of Metastasis-Directed Stereotactic Body Radiotherapy with Radioligand Therapy or Androgen Annihilation Therapy: A Comparison of Two Phase II Trials (ASTRO 2026) - P2 | "Whether an alternative strategy of adding androgen annihilation therapy (AAT; apalutamide plus abiraterone plus leuprolide) to SBRT would improve euPFS remains unknown. Both SBRT+RLT and SBRT+AAT improved euPFS over SBRT alone, while SBRT+RLT and SBRT+AAT achieved comparable euPFS. Given the numerical trend in grade =3 AEs favoring SBRT+RLT, in addition to the known quality of life impacts of hormonal therapy, SBRT+RLT appears to be a clinically attractive hormone-therapy sparing intensification strategy in men with oligorecurrent prostate cancer."

P2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Interpretable four-laboratory health record phenotyping of first-line apalutamide versus abiraterone in bone-metastatic prostate cancer (ESMO-AI 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302] (clinicaltrials.gov) - P3 | N=684 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform. (PubMed, Eur Urol) - "Abiraterone-based treatment intensification did not increase FRH compared to SOC alone. In M1 disease, abiraterone reduced rather than augmented fracture risk, most plausibly reflecting improved metastatic bone disease control."

Journal • P3 data • Genito-urinary Cancer • Musculoskeletal Diseases • Oncology • Prostate Cancer • Solid Tumor

Real-world safety and outcomes of first-line (1L) olaparib plus abiraterone (OLA+ABI) in metastatic castration-resistant prostate cancer (mCRPC), and a comparison with docetaxel (DOC) (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Apalutamide versus abiraterone acetate in metastatic hormone-sensitive prostate cancer: an international propensity score-matched real-world analysis (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Age-dependent differences in clinical benefit between abiraterone and enzalutamide in mCRPC: a post hoc analysis of the ProBio trial (ESMO 2026) - No abstract available

Clinical • Retrospective data • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Optimizing sequencing under constraint: efficacy of low-dose abiraterone in metastatic castration-resistant prostate cancer from a real-world study in Thailand (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Rinzimetostat, an Allosteric PRC2 Inhibitor Combined With Darolutamide: A Global Phase 3 Study in mCRPC Patients Previously Treated With Abiraterone Acetate (Himalayas-1) (ESMO 2026) - No abstract available

Clinical • P3 data • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer

Darolutamide vs Abiraterone Triplet Therapy and Survival in U.S. Veterans with Newly Diagnosed Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (ESMO 2026) - No abstract available

Metastases • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

Clinical Validation of a Tissue-Based Next-Generation Sequencing Kit for Identifying Patients with BRCA1/2-Mutated Prostate Cancer for Niraparib + Abiraterone Acetate and Prednisone Therapy (ESMO 2026) - No abstract available

Biomarker • Clinical • Next-generation sequencing • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2

Ethnicity-Based Comparative Analysis of Treatment Endpoints of 30,000 Metastatic Castration Resistance Prostate Cancer Patients on Abiraterone and Enzalutamide (ESMO 2026) - No abstract available

Clinical • Metastases • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Niraparib Plus Abiraterone and Prednisone in Metastatic Castration-Resistant Prostate Cancer: Results from the ProBio Platform Trial (ESMO 2026) - No abstract available

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Phase 1/2 study of a PARP1-selective inhibitor, EIK1003, in combination with abiraterone in patients with metastatic prostate cancer (mPC) (ESMO 2026) - No abstract available

Clinical • Combination therapy • Metastases • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway). (ASCO-GU 2026) - P2 | "In pts with mCRPC harboring BRCA1/2 or ATM alterations, abiraterone/prednisone + olaparib was well tolerated and resulted in significantly improved OS (median of >5 years) compared to either agent used alone or sequentially."

Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ATM • BRCA1 • BRCA2 • HRD

Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281. (ASCO-GU 2026) - P3 | "Common capi-associated AEs occur early and are clinically manageable. While pts in the capi+abi arm had more symptomatic AEs (eg diarrhea, rash) consistent with faster decline in self-reported PWB compared with pts in the pbo+abi arm, this did not affect other functional aspects of life (eg work, sleep) and overall HRQoL, allowing for continued treatment with capi+abi."

Clinical • Metastases • Patient reported outcomes • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • PTEN

67 Cu-SAR-bisPSMA leads to Undetectable Disease in Metastatic Castration-Resistant Prostate Cancer Patients: Two Case Reports From The Phase I/IIa SECuRE Trial (EANM 2026) - P1/2 | "Participant A (64 years) received prior definitive radiotherapy and androgen deprivation therapy (ADT), docetaxel for metastatic hormone-sensitive disease, and enzalutamide for mCRPC with palliative stereotactic body radiotherapy. Participant B (76 years) underwent salvage prostate fossa radiotherapy with ADT and later progressed to mCRPC treated with abiraterone and ongoing ADT... In these two cases from the SECuRE trial, ≤3 cycles of 67Cu-SAR-bisPSMA demonstrated marked anti-tumour activity in mCRPC, achieving undetectable disease by PSA and imaging, with most adverse events being mild and transient. These findings support the potential role of 67Cu-SAR-bisPSMA in mCRPC treatment."

Case report • Clinical • Metastases • P1/2 data • Castration-Resistant Prostate Cancer • Dry Eye Disease • Genito-urinary Cancer • Oncology • Ophthalmology • Prostate Cancer • Solid Tumor

Factors Associated with Completion of Radium-223 Treatment (EANM 2026) - "This indicates that the number of prior treatments (docetaxel, abiraterone, enzalutamide, cabazitaxel) does not significantly influence the likelihood of completing the six doses of Ra223; rather, other clinical factors, such as slow disease evolution and stability on hormone therapy, are more decisive. Completing the six-dose of Ra223 is the most significant prognostic factor for long-term survival in patients with mCRPC. Radiological progression and clinical deterioration are the primary barriers to therapeutic success, rather than the intrinsic toxicity of the radiopharmaceutical. Selecting patients whose disease evolves more slowly (prolonged sensitivity to castration) maximises the probability of completing treatment and optimising clinical outcomes."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor

177 Lu-PSMA Radioligand Therapy in Chemo-Naïve mCRPC Patients: Is There Added Benefit from ARPI Combination? (EANM 2026) - "Among them, 22/48 (46%) received 177Lu-PSMA RLT in combination with ARPI (7 enzalutamide,15 abiraterone). In our study, 177Lu-PSMA RLT was confirmed as an effective treatment option in chemo-naïve mCRPC patients. Concomitant ARPI use was associated with improved biochemical response, although this advantage was not confirmed in imaging outcomes or survival."

Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor • FOLH1

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) (clinicaltrials.gov) - P3 | N=1244 | Terminated | Sponsor: Merck Sharp & Dohme LLC | Completed ➔ Terminated; The study stopped due to futility

Trial termination • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC). (ASCO 2024) - P1/2 | "A Phase 2 trial in 129 patients with mCRPC who progressed on abiraterone demonstrated improved median radiographic progression-free survival (rPFS) when samotolisib, a dual PI3K-mTOR inhibitor, was added to enzalutamide. Secondary endpoints include rPFS rates at 9 and 12 months, overall rPFS, prostate-specific antigen response of ≥50% decrease from baseline at 4, 8, 12, and 16 weeks, overall response rate, duration of response, clinical benefit rate, overall survival rate at 18 and 24 months, and safety. The trial is currently open for enrollment (NCT06190899)."

Clinical • Combination therapy • Metastases • P1/2 data • Diabetes • Genito-urinary Cancer • Metabolic Disorders • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) (ESMO 2022) - P3 | "Background Landmark trials led to the integration of docetaxel (D) or novel hormonal agents (NHA) added to androgen deprivation therapy (ADT) into the treatment paradigm for mHSPC. Key secondary endpoints include rPFS assessed by blinded independent central review, castration-resistant prostate cancer-free survival, overall survival, time to pain progression, safety and pharmacokinetics. Enrollment is open at approximately 270 sites across 25 countries."

Clinical • Combination therapy • P3 data • Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Prostate Cancer • Solid Tumor • CCND1 • CDK4 • ER • HER-2

CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer. (ASCO 2024) - P2/3 | "Randomization to the ABEMA or placebo (PBO) plus ABI and predniso(lo)ne was stratified by prior docetaxel receipt for mHSPC, measurable disease, and radiographic progression at study entry. In patients with mCRPC, adding abemaciclib to abiraterone did not significantly increase rPFS. While no OS detriment was observed, secondary endpoints were not meaningfully improved. Overall, the combination was well tolerated, and safety was consistent with the known profiles of the individual medicines."

Clinical • Metastases • P3 data • Anemia • Breast Cancer • CNS Disorders • Genito-urinary Cancer • Hematological Disorders • Metastatic Castration-Resistant Prostate Cancer • Neutropenia • Oncology • Pain • Prostate Cancer • Psychiatry • Solid Tumor